ClinicalTrials.gg
CompletedNCT05868122Updated Nov 3, 2026Results posted

A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy

A Phase 3 interventional study of Acetaminophen/Naproxen Sodium Fixed Combination and Placebo in Pain, sponsored by Johnson & Johnson Consumer Inc. (J&JCI). Completed at 4 sites in United States. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Johnson & Johnson Consumer Inc. (J&JCI) (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies in Pain by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Pain · Johnson & Johnson.

Enrollment
48th of 88
143 · median 183
Started
2023
with 2 others
Phase 3
40 of 104
none open now
Registered
104th of 104
by date

Among the 104 studies in Pain by Johnson & Johnson, this one is the 48th largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2023, is one of 40 in phase 3, and was the 104th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 104 studies in Pain by Johnson & Johnson is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 104 studies in Pain by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to evaluate effectiveness of a fixed combination of acetaminophen/naproxen sodium compared with placebo for reduction of pain when administered as multiple doses over a 48-hour period.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females have a negative urine pregnancy at screening and on the morning of surgery
  • Weight of 100 pounds or greater and have a (BMI) of 17.5 to 38.0 (inclusive) at screening
  • Scheduled to undergo primary, unilateral, distal, first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures. Participants who have previously undergone bunionectomy on the contralateral foot will not be prohibited from enrolling in this study if performed greater than or equal to (>=) 6 months
  • Are able to comprehend and follow the requirements of the study (including pre-surgical instructions provided by the site and availability on scheduled visit dates) based upon research site personnel's assessment
  • Provide written (for participants who are below the age of legal consent, parent or legally authorized representative provides written informed consent and the participant provides written assent)
  • Participant agrees to the requirements
  • Are willing for this to be the only product used during the study
  • Have a negative urine drug screen at screening, and on day of surgical procedure. a) a positive drug screen for a known prescribed concomitant medication that is not otherwise exclusionary will not disqualify a participant; b) drug and alcohol screen results must be negative for a participant to receive study medication, a positive Tetrahydrocannabinol (THC) screen will only be exclusionary on day of surgery (Day 0)

Postoperative Inclusion Criteria

  • Participant reports both of the following after discontinuation of the popliteal block and before 2:00 PM on Day 1. a) moderate or severe pain on a 4-point categorical pain rating scale (with categories of none, mild, moderate, or severe; b) a score >= 5 on 11-point pain intensity-numerical pain rating scale (PI-NRS)
  • Participant is able to answer questions and follow commands, and appropriately participate in requisite pain evaluation assessments dictated in the protocol
  • The surgical procedure from incision to closure was not longer than 2 hours
  • The participant has had no evidence of respiratory insufficiency, hypotension, brady cardia, or any other abnormality, during or following surgery that, in the Investigator's opinion, significantly increases the risks of study drug administration
  • There were no significant deviations from the surgical protocol, anesthetic protocol, or specified analgesic regimen, that would, in the opinion of the Investigator, put the participant at risk of participation in the trial, confound the analgesic endpoints of the trial or cause concern regarding the participants ability to participate in the trial

Exclusion criteria

Exclusion Criteria:

  • Are female and are pregnant, breastfeeding, or currently trying to become pregnant
  • Are male with a pregnant partner or a partner who is currently trying to become pregnant
  • Have a known allergy or to: a) naproxen or other nonsteroidal anti-inflammatory drugs, including aspirin; b) oxycodone or other opioids; c) acetaminophen; d) any other drug listed in the surgical and anesthetic protocol or postoperative pain management of the study protocol
  • Have presence or a history of major medical condition that in the investigator's opinion may jeopardize the participant's safety or well-being, or the integrity of the study, example; a) hepatic, renal, pancreatic, gastrointestinal, cardiovascular, cerebrovascular, or thyroid diseases; b) history of head injury or seizures; c) history of respiratory depression or lung problems such as but not limited to asthma or ; d) psychiatric disorders (although participants with well-controlled depression or anxiety, who are on a stable dose of medication may be allowed); e) problems urinating; f) history of blockage or narrowing of the stomach or intestines; g) uncontrolled hypertension indicated as systolic blood pressure >=160 millimetres of mercury (mmHg) or diastolic blood pressure >=100 mmHg. Blood pressure may be repeated after the participant has remained in a rested state for at least 10 minutes. The final blood pressure value will be used for eligibility; h) uncontrolled diabetes, as determined by the investigator, in the last six months; i) medical conditions that would interfere with normal pain perception (example diabetic neuropathy) in the opinion of the Investigator
  • Have a history of endoscopically documented peptic ulcer disease or bleeding disorder in the last two years
  • Are not able to swallow whole large tablets or capsules
  • Participants will be excluded from the study for any of the following:a) routine use of oral analgesics >=3 times per week for a medical condition unrelated to bunion pain in the 2 months prior to surgery; b) opioid tolerant, that is, the participant is currently taking or has taken a chronic opioid for pain at a dose greater than or equal to 10 milligrams (mg) hydrocodone per day, more than 1 out of 7 days per week, in the 2 months prior to surgery; c. History of chronic tranquilizer use, heavy drinking, opioid abuse, or other substance abuse, as judged by the Investigator, in the last five years. Heavy drinking is defined as the use of more than four standard drinks daily or more than 14 drinks a week for men, and more than three standard drinks daily or more than seven standard drinks in a week for women. Standard drink refers to 14 grams (g) (0.6 ounce [oz.]) of pure alcohol, which is approximately 12 oz. of beer, 8 oz. of malt liquor, 5 oz. of wine, 1.5 oz. or "shot" of 80 proof distilled spirits or liquor (example., gin, rum, vodka, or whiskey); d) use of any drugs, (except for topical corticosteroids), or injectable or oral anticoagulants (example., heparin, Lovenox, Xarelto, Eliquis, Pradaxa, Coumadin, Miradon) within 2 weeks prior to surgery; e) use of monoamine oxidase inhibitors within 2 weeks prior to surgery; f) use of alcohol within 24 hours prior to surgery; g) consumption of methylxanthine containing products (example, chocolate bars or chocolate beverages, coffee, tea, cola or caffeinated energy drinks), tobacco, or nicotine containing products (example, cigarettes, cigars, nicotine replacement therapies, vaping devices) less than (\<) 12 hours prior to surgery; h) use of any other over-the-counter or prescription medications or supplements that, in the Investigator's opinion, may cause participation in the study to jeopardize the participant's safety or well-being, or may jeopardize the integrity of the study, within 5 days (or longer if the investigator deems a longer washout is warranted) prior to surgery
  • Have a positive test for (HIV) antibody, surface antigen (HBsAg), or virus antibody (anti-HCV)
  • Have participated in any interventional clinical trials within 30 days before screening
  • Are related to those persons involved directly or indirectly with the conduct of this study (that is., Principal Investigator, sub-investigators, study coordinators, other site personnel, employees of Johnson \& Johnson [J\&J] subsidiaries, contractors of J\&J, and the families of each)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Acetaminophen/Naproxen Sodium Fixed Combination

    Participants will receive oral doses of two Acetaminophen/Naproxen Sodium Fixed Combination tablets taken with water. Multiple doses will be administered over a 48-hour period.

    Drug: Acetaminophen/Naproxen Sodium Fixed Combination

  • Placebo comparator
    Placebo

    Participants will receive oral doses of two placebo tablets taken with water. Multiple doses will be administered over a 48-hour period.

    Drug: Placebo

Interventions

  • DrugAcetaminophen/Naproxen Sodium Fixed Combination

    Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.

  • DrugPlacebo

    Placebo will be administered orally.

06

What researchers measure

Primary outcomes

  1. Time-weighted Sum of Pain Intensity Difference Score From 0 to 24 Hours After Dosing (SPID 0-24)

    Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-24 hours. PID is ranging from 0 to 10 point and SPID0-24 ranging from 0 to 240. A higher value of SPID indicated greater pain relief.

    Time frame: Baseline (0 hour) up to 24 hours post-dose

Secondary outcomes

  1. Time-weighted SPID Score From 0 to 12 Hours After Dosing (SPID 0-12)

    Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-12 hours. PID is ranging from 0 to 10 point and SPID0-12 ranging from 0 to120. A higher value of SPID indicated greater pain relief.

    Time frame: Baseline (0 hour) up to 12 hours post-dose

  2. Time-weighted SPID From 0 to 48 Hours After Dosing (SPID 0-48)

    Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-48 hours. PID is ranging from 0 to 10 point and SPID0-48 ranging from 0 to 480. A higher value of SPID indicated greater pain relief.

    Time frame: Baseline (0 hour) up to 48 hours post-dose

  3. Time to Confirmed Perceptible Pain Relief (TCPR)

    TCPR is defined as the time (in minutes) to perceptible pain relief as indicated on the first stopwatch, provided that the participant also stopped the second stopwatch indicating meaningful pain relief.

    Time frame: Up to 12 hours

  4. Time to Meaningful Pain Relief (TMPR)

    TMPR is defined as the time (in minutes) to meaningful pain relief as indicated on the second stopwatch.

    Time frame: Up to 12 hours

  5. Time to First Use of Rescue Medication

    Time to first use of rescue medication was measured as the elapsed time from when investigational product was given until the time rescue medication was first given.

    Time frame: Up to 48 hours

  6. Proportion of Participants Who Use Rescue Medication During the First 12 Hours

    Proportion of participants who use rescue medication during the first 12 hours was reported.

    Time frame: Up to 12 hours

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Started7271
Completed6755
Not completed516
Withdrew: Adverse event02
Withdrew: Lack of efficacy414
Withdrew: Personal reasons10

Outcome measures

PrimaryTime-weighted Sum of Pain Intensity Difference Score From 0 to 24 Hours After Dosing (SPID 0-24)

Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-24 hours. PID is ranging from 0 to 10 point and SPID0-24 ranging from 0 to 240. A higher value of SPID indicated greater pain relief.

Time frame:
Baseline (0 hour) up to 24 hours post-dose
Reported as:
Least squares mean · units on a scale*hours
Time-weighted Sum of Pain Intensity Difference Score From 0 to 24 Hours After Dosing (SPID 0-24)
units on a scale*hoursAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Time-weighted Sum of Pain Intensity Difference Score From 0 to 24 Hours After Dosing (SPID 0-24)48.44 ± 5.07414.16 ± 5.125
SecondaryTime-weighted SPID Score From 0 to 12 Hours After Dosing (SPID 0-12)

Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-12 hours. PID is ranging from 0 to 10 point and SPID0-12 ranging from 0 to120. A higher value of SPID indicated greater pain relief.

Time frame:
Baseline (0 hour) up to 12 hours post-dose
Reported as:
Least squares mean · units on a scale*hours
Time-weighted SPID Score From 0 to 12 Hours After Dosing (SPID 0-12)
units on a scale*hoursAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Time-weighted SPID Score From 0 to 12 Hours After Dosing (SPID 0-12)15.22 ± 2.4502.61 ± 2.467
SecondaryTime-weighted SPID From 0 to 48 Hours After Dosing (SPID 0-48)

Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-48 hours. PID is ranging from 0 to 10 point and SPID0-48 ranging from 0 to 480. A higher value of SPID indicated greater pain relief.

Time frame:
Baseline (0 hour) up to 48 hours post-dose
Reported as:
Least squares mean · units on a scale*hours
Time-weighted SPID From 0 to 48 Hours After Dosing (SPID 0-48)
units on a scale*hoursAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Time-weighted SPID From 0 to 48 Hours After Dosing (SPID 0-48)151.50 ± 11.09768.31 ± 11.195
SecondaryTime to Confirmed Perceptible Pain Relief (TCPR)

TCPR is defined as the time (in minutes) to perceptible pain relief as indicated on the first stopwatch, provided that the participant also stopped the second stopwatch indicating meaningful pain relief.

Time frame:
Up to 12 hours
Reported as:
Median · Minutes
Time to Confirmed Perceptible Pain Relief (TCPR)
MinutesAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Time to Confirmed Perceptible Pain Relief (TCPR)NA (15 to 720)NA (0 to 720)
SecondaryTime to Meaningful Pain Relief (TMPR)

TMPR is defined as the time (in minutes) to meaningful pain relief as indicated on the second stopwatch.

Time frame:
Up to 12 hours
Reported as:
Median · Minutes
Time to Meaningful Pain Relief (TMPR)
MinutesAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Time to Meaningful Pain Relief (TMPR)NA (43.6 to 720)NA (3.0 to 720)
SecondaryTime to First Use of Rescue Medication

Time to first use of rescue medication was measured as the elapsed time from when investigational product was given until the time rescue medication was first given.

Time frame:
Up to 48 hours
Reported as:
Median · Minutes
Time to First Use of Rescue Medication
MinutesAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Time to First Use of Rescue Medication177.5 (105.0 to 252.0)98.0 (79.0 to 118.0)
SecondaryProportion of Participants Who Use Rescue Medication During the First 12 Hours

Proportion of participants who use rescue medication during the first 12 hours was reported.

Time frame:
Up to 12 hours
Reported as:
Number · Percent of participants
Proportion of Participants Who Use Rescue Medication During the First 12 Hours
Percent of participantsAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
Proportion of Participants Who Use Rescue Medication During the First 12 Hours80.6 (71.0 to 89.0)93.0 (85.8 to 97.7)

Adverse events

Collected over Adverse events were collected starting from the time a subject signed and dated the informed consent and until the completion of the subject's last study-related procedure, including contact for follow-up of safety, up to Day 10.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acetaminophen/Naproxen Sodium Fixed Combination0/72 (0%)0/72 (0%)12/72 (16.7%)
Placebo0/71 (0%)0/71 (0%)23/71 (32.4%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventAcetaminophen/Naproxen Sodium Fixed CombinationPlacebo
HeadacheNervous system disorders3/729/71
NauseaGastrointestinal disorders3/725/71
ConstipationGastrointestinal disorders4/723/71
VomitingGastrointestinal disorders1/723/71
Gastrooesophageal reflux diseaseGastrointestinal disorders0/722/71
DizzinessNervous system disorders0/722/71
DiarrhoeaGastrointestinal disorders0/721/71
DyspnoeaRespiratory, thoracic and mediastinal disorders0/721/71
Sinus congestionRespiratory, thoracic and mediastinal disorders0/721/71
RashSkin and subcutaneous tissue disorders1/721/71

Baseline characteristics

Age, Continuous
Age, Continuous(years)Acetaminophen/Naproxen Sodium Fixed CombinationPlaceboTotal
Mean44.9 ± 11.9043.6 ± 11.5344.3 ± 11.69
Age, Customized
Age, Customized(Participants)Acetaminophen/Naproxen Sodium Fixed CombinationPlaceboTotal
<18 years000
18-30 years121022
31-40 years151732
41-50 years162036
51-65 years292453
>65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Acetaminophen/Naproxen Sodium Fixed CombinationPlaceboTotal
Female6058118
Male121325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Acetaminophen/Naproxen Sodium Fixed CombinationPlaceboTotal
Hispanic or Latino272855
Not Hispanic or Latino454388
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Acetaminophen/Naproxen Sodium Fixed CombinationPlaceboTotal
American Indian or Alaska Native112
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American222042
White414485
More than one race000
Unknown or Not Reported426
08

Study locations

4 sites
  • Lotus Clinical Research, LLC
    New Providence, New Jersey 07974, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • The Heights Hospital / Memorial Herman Village
    Houston, Texas 77008, United States
  • Endeavor Clinical Trails
    San Antonio, Texas 78240, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in May 2024, 8 months.

Results were first posted in Nov 2026, 2 years 5 months after primary completion. A results delay was requested in May 2025.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
May 22, 2023
StartActual
Sep 7, 2023
Primary completionActual
May 25, 2024
CompletionActual
May 30, 2024
Results delay requested
May 13, 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTime-weighted Sum of Pain Intensity Difference Score fromFrom 0 to 24 Hours After Dosing (SPID 0-24)Time frame: 0 to 24 hours post-dose → Baseline (0 hour) up to 24 hours post-dose
Nov 3, 2026
Documents
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedTime-weighted SPID Score fromFrom 0 to 12 Hours After Dosing (SPID 0-12)Time frame: 0-12 hours post-dose → Baseline (0 hour) up to 12 hours post-dose
  • EditedTime-weighted SPID fromFrom 0 to 48 Hours After Dosing (SPID 0-48)Time frame: 0-48 hours post-dose → Baseline (0 hour) up to 48 hours post-dose
  • EditedTime to First useUse of Rescue MedicationTime frame: Up to 48 hours
  • EditedPercentageProportion of Participants who useWho Use Rescue Medication During the First 12 HoursTime frame: Up to 12 hours
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTime-weighted Sum of Pain Intensity Difference Score fromFrom 0 to 24 Hours After Dosing (SPID 0-24)Time frame: 0 to 24 hours post-dose → Baseline (0 hour) up to 24 hours post-dose
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedTime-weighted SPID Score fromFrom 0 to 12 Hours After Dosing (SPID 0-12)Time frame: 0-12 hours post-dose → Baseline (0 hour) up to 12 hours post-dose
    • EditedTime-weighted SPID fromFrom 0 to 48 Hours After Dosing (SPID 0-48)Time frame: 0-48 hours post-dose → Baseline (0 hour) up to 48 hours post-dose
    • EditedTime to First useUse of Rescue MedicationTime frame: Up to 48 hours
    • EditedPercentageProportion of Participants who useWho Use Rescue Medication During the First 12 HoursTime frame: Up to 12 hours
    + 4 other changes: verification date, registry dates, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05868122
Responsible party
Sponsor
First posted
May 22, 2023
Start date
Sep 7, 2023
Primary completion
May 25, 2024
Completion
May 30, 2024
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Marsha Tharakan, MD, DDS
study director · Kenvue Brands LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion